| 000 | 01790 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517090345.0 | ||
| 264 | 0 | _c20170724 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1365-2133 | ||
| 024 | 7 |
_a10.1111/bjd.14626 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBattistella, M | |
| 245 | 0 | 0 |
_aKIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. _h[electronic resource] |
| 260 |
_bThe British journal of dermatology _cAug 2016 |
||
| 300 |
_a325-33 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKi-1 Antigen _xmetabolism |
| 650 | 0 | 4 |
_aKiller Cells, Natural _xphysiology |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xmetabolism |
| 650 | 0 | 4 |
_aLymphoma, Large-Cell, Anaplastic _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptors, KIR2DL2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSkin _xmetabolism |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aJanin, A | |
| 700 | 1 | _aJean-Louis, F | |
| 700 | 1 | _aCollomb, C | |
| 700 | 1 | _aLeboeuf, C | |
| 700 | 1 | _aSicard, H | |
| 700 | 1 | _aBonnafous, C | |
| 700 | 1 | _aDujardin, A | |
| 700 | 1 | _aRam-Wolff, C | |
| 700 | 1 | _aKadin, M E | |
| 700 | 1 | _aBensussan, A | |
| 700 | 1 | _aBagot, M | |
| 700 | 1 | _aMichel, L | |
| 773 | 0 |
_tThe British journal of dermatology _gvol. 175 _gno. 2 _gp. 325-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjd.14626 _zAvailable from publisher's website |
| 999 |
_c25885923 _d25885923 |
||